Darvish Nissim 4

4 · Chemomab Therapeutics Ltd. · Filed Mar 14, 2022

Form 4

Period: 2022-03-11

Director

Transactions

Purchase
American Depositary Shares
2022-03-11$4.28/sh+1,200$5,136→ 1,200 total
Award
Option to Purchase American Depositary Shares
2021-04-19+11,884→ 11,884 total
Exercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying)
Award
Option to Purchase American Depositary Shares
2021-03-16+10,123→ 10,123 total
Exercise: $0.80Exp: 2026-10-27→ American Depositary Shares (10,123 underlying)
Award
Option to Purchase American Depositary Shares
2022-03-07+6,820→ 6,820 total
Exercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying)

Footnotes (6)

[F1]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
[F2]The ADSs are held of record directly by the Ashdanit Medical Ltd. (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole ultimate beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
[F3]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
[F4]These options vest and become exercisable in their entirety on March 16, 2023, subject to the Reporting Person's continued service.
[F5]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
[F6]The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

Documents

1 file